Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma

European Journal of Haematology

Volumn 59, Issue 2, 1997, Pages 100-104

  Kars, Ayşe ^a   Çelik, Ismail ^a   Kansu, Emin ^a   Tekuzman, Gülten ^a   Özişik, Yavuz ^a   Güler, Nilüfer ^a   Barişta, Ibrahim ^a   Güllü, Ibrahim ^a   Yalçin, Şuayib ^a   Altundaǧ, Kadri ^a   Zengin, Nurullah ^a   Türker, Alev ^a   Hayran, Mutlu ^a   Baltali, Eşmen ^a   Firat, Dinçer ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Alpha interferon; Induction; Maintenance; Multiple myeloma; VAD chemotherapy

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOMODULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL;

EID: 8544242686     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00732.x     Document Type: Article

References (17)

1. GREGORY WM, RICHARDS MA, MALPAS JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992: 10: 334-342.
2. BARLOGIE B, SMITH L, ALEXANIAN R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984: 310: 1353-1356.
3. SAMSON D, NEWLAND A, KEARNEY J, et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 1989: 2: 882-885.
4. QUESADA JR, ALEXANIAN R, HAWKINS M, et al. Treatment of multiple myeloma with recombinant alpha-interferon. Blood 1986: 67: 257-278.
5. COOPER MR, DEAR K, MCINTYRE OR, et al. A randomized clinical trial comparing melphalan/prednisone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J Clin Oncol 1993: 11: 155-160.
6. THE NORDIC MYELOMA STUDY GROUP. Interferon-α2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. Ann Intern Med 1996: 124: 212-222.
7. SALMON SE, CROWLEY JJ, GROGAN TM, et al. Combination chemotherapy, glucocorticoids and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1994: 12: 2405-2414.
8. WESTIN J, RÖDJER S, TURESSON I, et al. Interferon alpha-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study. Br J Haematol 1995: 89: 561-568.
9. MANDELLI F, AVVISATI G, AMADORI S, et al. Maintenance treatment with recombinant interferon alpha-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med 1990: 322: 1430-1434.
10. BROWNMAN GP, BERGSAGEL D, SICHERI D, et al. Randomized trial of interferon maintenance in multiple myeloma: A study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1995: 13: 2354-2360.
11. DURIE BGM, SALMON SE. A clinical staging system for multiple myeloma. Cancer 1975: 36: 842-854.
12. CHRONIC LEUKEMIA-MYELOMA TASK FORCE OF THE NATIONAL CANCER INSTITUTE. Proposed guidelines for protocol studies. II. Plasma cell myeloma. Cancer Chemother Rep 1973: 4: 145-158.
13. KAPLAN E, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
14. COX DR. Regression models and life-tables. J R Stat Soc B 1972: 34: 187-202.
15. ALEXANIAN R, BARLOGIE B, TUCKER S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990: 33: 86-89.
16. ANDERSON H, SCARFFE JH, RANSON M, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995: 71: 326-330.
17. ABRAHAMSON GM, BIRD JM, NEWLAND AC, et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996: 94: 659-664.